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ACC American College of Cardiology 
ACE angiotensin-converting enzyme inhibitor 
ARB angiotensin receptor blocker 
AHA American Heart Association 
BMI body mass index 
BP blood pressure 
BPM beats per minute 
CI chronotropic index 
CRF cardiorespiratory fitness 
CAD coronary artery disease 
CV cardiovascular 
DBP diastolic blood pressure 
DTS Duke Treadmill Score 
ECG electrocardiogram (also electrocardiography, electrocardiographic)  
FAC functional aerobic capacity 
HR heart rate 
LBBB left bundle brach block 
LVH left ventricular hypertrophy 
RPE rating of perceived exertion 
SD standard deviation 








It is important for both good patient care and health care economics to gain the most 
information possible from each test performed. This statement is equally valid for the 
exercise test, which provides both diagnostic and prognostic information (1). This 
means not only looking at the ST segment response, but also accurately reporting and 
identifying the significance of functional aerobic capacity (FAC) and exercise heart rate 
(HR) responses, including the HR recovery.  
Ever since the concept of HR recovery on the exercise test in clinical practice was 
proposed by Lauer and colleagues in 1999 (2), investigations have consistently 
demonstrated its ability to identify higher risk patients in mixed cohorts – with and 
without documented coronary artery disease (3), in patients referred for nuclear stress 
testing and possible coronary angiography (4), and patients with symptomatic coronary 
artery disease (5).  HR recovery is impaired in patients with obstructive sleep apnea (6), 
silent myocardial ischemia (7), heart failure with preserved ejection fraction (8), and 
Type 2 diabetes (9), though these studies did not report long-term outcomes.  
Diabetes is associated with an excess long-term mortality, primarily due to 
associated cardiovascular diseases. It is frequently associated with autonomic 
neuropathy, one manifestation of which is an impaired HR response to exercise. Both 
impaired HR response to exercise and diabetes have been shown to be strong and 
independent predictors of mortality (10), but the effect of diabetes on exercise HR and 
the potential role of impaired HR in mortality in diabetic patients have not been 
adequately investigated.   
The prognostic potential of HR recovery in a primary prevention population without 
documented coronary artery disease has not been fully examined either. In primary 
prevention cohort, cardiovascular (CV) deaths may not constitute the majority of all 
deaths, so it is important to know if non-CV deaths are also related to HR recovery.   
Another issue is whether adjusting the HR recovery for different subgroups will 
improve its performance. Among exercise test prognostic factors, FAC is adjusted for 
age and sex, while peak exercise HR is adjusted for age and beta blocker use – either 
ignored in beta-blocked patients or given a different age-adjusted target (11). It is 




and whether adjustment for any of these factors improves its performance (12). These 
questions represent the focus of the current investigation while also an attempt of 
validating the prognostic value of HR recovery in a primary prevention cohort. We 
extended our examination to diabetic patients, and assessed resting HR, peak HR, HR 
reserve, HR recovery and calculated the chronotropic index (CI) according to diabetes 

























1.1. Exercise Testing  
Electrocardiography (ECG) during stress testing is an essential tool for diagnosis 
and management of patients with various CV diseases. Its significance is based on 
simplicity, easy availability, short time to perform and interpret, and high informative 
value in special cases. Exercise testing is a CV stress test that uses treadmill or bicycle 
exercise with ECG and blood pressure (BP) and HR monitoring (Figure 1). 
It is one of the most common non-invasive techniques to diagnose coronary artery 
disease (CAD), determine its prognosis and follow patients longitudinally. Applying 
exercise testing, we can assess FAC, exercise related symptoms and hemodynamic 
changes (HR and BP). We can detect ECG abnormalities not present at rest, including 
exercise induced arrhythmias, conduction disorders and myocardial ischemia, moreover 
we can also identify masked hypertension.  
 
Figure 1. Exercise testing to detect myocardial ischemia   
https://thoracickey.com/stress-testing-and-nuclear-imaging/  
      Recently, the use of the stress testing has expanded to include testing for FAC, 
chronotropic incompetence (CI), cardiac rehabilitation, valvular heart disease, 




1.1.1. Indications for Exercise Testing 
Exercise testing has been used for myocardial ischemia provocation and 
identification for more than six decades, and during this time additional purposes for 
testing have evolved. Exercise testing now is used widely for the following:  
• Detection of CAD in patients with chest pain (chest discomfort) syndromes or 
potential symptom equivalents (Figure 2) 
• Evaluation of the anatomic and functional severity of CAD  
• Prediction of CV events and all-cause death  
• Evaluation of physical capacity and effort tolerance  
• Evaluation of exercise-related symptoms  
• Assessment of chronotropic competence, arrhythmias, and response to implanted 
device therapy  
• Assessment of the response to medical interventions.  
Understanding the purpose of the individual exercise test allows the test supervisor 
to determine an appropriate methodology and to select test end points that maximize test 
safety and obtain needed diagnostic and prognostic information. During the past several 
decades, exercise testing has been focused increasingly on assessment of CV risk, not 
simply on the detection of coronary obstruction. Ultimately, improved clinical outcome 





Figure 2. Evaluation for hemodynamically significant coronary artery disease (CAD) in clinically stable 

















1.1.2. Exercise Test Protocols 
Bruce protocol is the most best known protocol in the world. Because of its 
universality, reproducibility, and practicality, the protocol remains one of the most 
widely used methods for diagnosing ischemic heart disease. Patients commonly start 
exercising on a treadmill set at 1.7 miles per hour and a 10% grade, and increase to a 
maximum speed of 6.0 miles per hour and a 22% grade.  
1.1.3. Risk Prediction  
The prognostic predictive value of exercise HR parameters has been studied in a 
wide range of CV populations and has proved to be an independent powerful predictor 
of mortality (3,15-22).  
Cardiorespiratory Fitness 
The strongest predictor of survival found on exercise treadmill testing is functional 
aerobic capacity, which means how much exercise a patient can sustain, generally 
indexed to age and sex. Exercise capacity has proved to be a strong and independent 
predictor for mortality in both patients with and without CV diseases and is more 
powerful than established CV risk factors. The prognostic power of exercise capacity is 
the same in healthy individuals and patients with CV diseases (23). Higher level of 
cardiorespiratory fitness is associated with lower risk of development of prediabetes, 
metabolic syndrome, type 2 diabetes mellitus and several types of cancer. According to 
several studies, every 1-MET increase in exercise performance means 10-25% 
improvement in survival mainly focusing on CV or total mortality. Moreover, the 
addition of cardiorespiratory fitness to traditional risk factors significantly improves the 
reclassification of risk for adverse outcomes (24). 
Among exercise test variables, exercise capacity was shown to be the strongest 
predictor of CV death and all-cause mortality in both genders (25). Mora et al. found 
that the prognostic value of stress testing derives not from ischemic ECG changes, but 
from fitness-related variables in asymptomatic women. They combine exercise capacity 
and HR recovery (with <22/min cut-off) and report CV and all-cause mortality in 
women (26). A large study including only men also reported that low cardiorespiratory 





Heart Rate Recovery 
HR recovery is defined as the rate at which heart rate decreases within the following 
minutes after the peak exercise. It reflects the dynamic balance of autonomuos nervous 
system, and coordinated interplay between parasympathetic reactivation and 
sympathetic withdrawal (28). While the increase of HR during exercise is considered to 
be due to the combination of parasympathetic withdrawal and sympathetic activation, 
HR decrease immediately after exercise is considered to be a function of the 
reactivation of the parasympathetic nervous system. As increased vagal activity has 
been associated with a reduction in the risk of death, the rate of recovery of the HR 
immediately after exercise has shown to be an important prognostic marker (2). 
Moreover, in recent years, there has been a large body of epidemiological evidence that 
HR recovery is a powerful predictor of overall mortality, independent of workload, the 











Figure 4. Estimates of the relative risk of death within six years according to heart-rate recovery one 
minute after cessation of exercise. Circles represent the relative risk of death for each of the quintiles as 
compared with the quintile with the greatest reduction (5th). Dashed lines represent the 95 percent 
confidence interval (2). 
 
Chronotropic incompetence 
Chronotropic incompetence is another prognostically important variable defined by 
the failure to reach 85% of the maximum predicted heart rate (20). Heart rate response 
is important during exertion because it measures how well the patient’s cardiac output 





Duke Treadmill Score 
Perhaps the most popular prognostic risk score used for the exercise test is the Duke 
Treadmill Score (DTS). The DTS is calculated by subtracting 5 times the ST depression 
(measured in mm) and 4 times the angina score (no angina=0, non-limiting angina=1, 
and test-limiting angina=2) from the total exercise duration (measured in minutes) on 
the standard Bruce protocol. Subjects are considered low risk if they score 5 or above, 
intermediate risk if they score between 4 and -10, and high risk if they score -11 and 
below. Subjects with a high-risk DTS are much more likely to have triple-vessel or left 



















2. Objectives of the Studies 
We have had a strong cooperation with Mayo Clinic Cardiovascular Health Clinic, 
Rochester, USA since 2014. In order to study HR responses to exercise, we assessed the 
large Mayo Integrated Stress Center Database (MISC). This database contains exercise 
testing data of almost 140000 patients with more than 200000 exercise tests covering 
approximately 32 years. 
1. Our first aim was to study exercise HR responses in a primary prevention 
population with a focus of HR recovery  
• to determine if HR recovery varies by age, sex, and beta blocker use, and 
whether adjustment for any of these factors improves its performance  
• to validate the prognostic value of HR recovery in a primary prevention 
cohort and determine its long-term prognostic significance. 
2. Our second aim was to extend our research to diabetic patients and investigate 
HR responses to exercise  
• to study the effect of diabetes on exercise HR parameters: resting HR, 
peak HR, HR reserve, HR recovery and chronotropic index (CI) 
















This was a retrospective study approved by Mayo Clinic Rochester Institutional 
Review Board. Subjects not consenting to have their data used in research under 
Minnesota Statute (§144.335) were excluded. (29)  
3.1. Participants  
Patients who underwent exercise treadmill testing from September 21, 1993 through 
December 20, 2010 were identified retrospectively using the Mayo Clinic Integrated 
Stress Center (MISC) database.   
Inclusion criteria were as follows: non-imaging stress test, Minnesota resident, 
symptom-limited treadmill test performed on the Bruce protocol. Minnesota residents 
were more likely than non-Minnesota residents to have follow-up medical evaluation at 
Mayo, and their vital status was readily available from the Mayo Clinic records and the 
Minnesota Death Index. The study cohort was limited to patients aged ≥ 20 years (in an 
attempt to limit referral bias) and < 90 years, because there were very few extremely 
elderly patients in the database. For the HR recovery analyses we included only patients 
between age 30-79 years.  
Tests were excluded if the patient (1) had documented history of cardiovascular 
(CV) disease, including ischemic heart diseases, heart failure, cardiac surgery, structural 
or valvular heart diseases, major arrhythmias, defibrillator or pacemaker, congenital 
heart diseases, cerebrovascular diseases, and peripheral vascular diseases; (2) the test 
was not symptom-limited but stopped because of ST changes, major arrhythmias, or 
abnormal blood pressure response; (3) active recovery for at least 1 minute was not 
completed; 4) peak exercise or 1-minute recovery HR were impaired by a paroxysmal 
arrhythmia. Where multiple qualifying tests were available for a given patient, the first 
test chronologically was chosen to maximize follow-up.   
3.2. Clinical Data 
Demographic and clinical information were collected prospectively at the time of 
the stress study. HR and other exercise data were uploaded into the database 
electronically from the GE CASE stress testing systems (Milwaukee, WI). Patient 




from patient medical charts and patient interview at the time of the exercise test. We 
specifically looked for diabetes mellitus (defined by prior diagnosis or receiving 
glucose-lowering medication), hypertension (defined by prior diagnosis or receiving 
anti-hypertension medication), obesity (defined as BMI ≥ 30 kg/m2), past and current 
smoking. Medication use – beta blockers, calcium channel blockers, aspirin, statins, 
ACE-inhibitors or angiotensin receptor blockers, and diabetic treatment drugs – oral 
hypoglycemics and insulin – was available in the database.  
3.3. Exercise Test Protocol and Variables 
Symptom-limited treadmill exercise testing was performed on usual medications 
using the standard Bruce protocol according to ACC/AHA guidelines (30,31). Resting 
HR and blood pressure (BP) measurements were obtained in the standing position. 
Symptoms, BP, HR, rating of perceived exertion (RPE) – measured by the Borg 
scale RPE scale, a frequently used quantitative measure of perceived exertion during 
execise – and workload were electronically entered into the database during the final 
minute of each stage of exercise, peak exercise, 1 and 3 minutes of active recovery at 
1.7 MPH/0% grade, and 6 minutes post-peak exercise in seated recovery.   
Exercise test interpretation data including reason for termination, symptoms, 
abnormal signs, and exercise electrocardiographic (ECG) analysis were added to the 
database immediately after the test. FAC was expressed as 100% x actual performance 
time/predicted performance time based on previous publications from our laboratory 
(32).  Peak HR was also expressed as percent predicted peak HR (33). HR reserve was 
calculated as the difference between peak and resting HR. CI was defined as HR reserve 
divided by the predicted HR reserve as previously reported in our laboratory for healthy 
men and women(33) and defined as abnormal if < 0.8 (16,20,21). HR recovery was 
calculated as peak exercise HR minus HR at 1 minute of active recovery at 1.7 
MPH/0% grade and was considered abnormal if < 13 beats/minute (3). An abnormal 
exercise ECG was defined as any ST depression or elevation > 1.0 mm irrespective of 
the resting ECG, while an abnormal exercise ECG was considered positive only if the 
resting ECG did not present significant ST-T abnormalities, the patient was not taking 





3.4. Mortality Outcomes 
Outcomes were taken from Mayo Clinic patient records and the Minnesota Death 
Index, which was reviewed in September 2014 (Research Aim 2) and March 2016 
(Research Aim 1). Follow-up was calculated as the time from the stress test to death 
(identified by the Minnesota Death Index as last date of vital status). This methodology 
provides 100% complete follow-up data. For the HR recovery analyses, CV and non-
CV deaths weredivided. A death was considered to be CV-related if a CV condition was 
included among the first 3 listed causes in the Minnesota Death Index; otherwise the 
death was considered non-CV. Mortality data were classified using International 
Classification of Diseases (ICD) 9 (391, 391.9, 394-398, 402, 404, 410-414, 415-417, 
420-429, 430-438, 440-448, 451-454, 456-459) and ICD 10 (I101, I05-I09, I11, I13, 
I20-I25, I26-I28, I30-I52, I60-69, I70-I79, I80-89) codes.  
3.5. Statistical Analysis 
Patient characteristics, outcomes, and exercise data were analyzed by decade of age.  
Differences among continuous variables by age group were assessed by the analysis of 
variance under the general linear model with multiple comparisons handled by Tukey’s 
method, while Pearson’s Chi-Squared Test of continuity was used to test age group 
differences in discrete variables.  Statistics were performed using SAS 9.4 (Raleigh, 
NC).  P < .05 was considered significant for all analyses. 
Research Aim 1   
Similar to a previous paper on peak HR by age and sex from our laboratory (33), the 
first step in the analysis was to determine factors that significantly affect HR recovery 
using stepwise multivariate regression, then to create a “pure cohort” by eliminating 
patients with those factors. This allowed us to identify the true physiologic change in 
HR recovery with age and sex. The next step in the analysis was to determine if the 
standard definition of abnormal HR recovery of < 13 bpm would predict the outcomes 
of total death, CV death, and non-CV death in this primary prevention dataset using the 
whole cohort. Cox Proportional Hazards Regression was employed for this analysis. 
Further analyses were stratified by age, sex, FAC, presence of hypertension, diabetes, 
current smoking and use of a HR-lowering drug. Differences in Hazard ratios between 




Research Aim 2 
Multivariable linear regression analysis was used to identify the effects of diabetes 
on HR adjusted for age, sex, and HR-lowering drugs then in a larger model including 
current smoking, hypertension, abnormal exercise ECG and type of diabetic treatment. 
For the simple model we chose factors that have a well-established effect on HR 
variables (33), while the full model is more exploratory. We determined the effect of 
exercise HR responses on total mortality in diabetics and non-diabetics using by Cox 
hazard regression first in the simple adjustment model and then in the extended 
adjustment model, as described above. We also performed Cox regression to compared 
mortality according to 0, 1, or 2 of the exercise HR abnormalities (abnormal HR 
























4.1. Study Population 
A total of 19551 patients were available for the HR recovery analysis. Their 
demographic and clinical data, stratified by decade of age, are provided in Table 1, 
along with the long-term outcome data – shown below in Table 1 for convenience.   
 
Table 1. Baseline characteristics and outcomes in the five age groups for the full clinical cohort. 
 
Age: 30-39 
N = 2664 
Age: 40-49 
N = 6703 
Age: 50-59 
N = 6047 
Age: 60-69 
N = 3112 
Age 70-79 
N = 1025 
P 
Age (years) 35.7 ± 2.81 44.7 ± 2.82 54.0 ± 2.93 63.9 ± 2.84 73.0 ± 2.65 < .0001 
Female 810 (30.4)1 2170 (32.4)1 2097 (34.7)2 2171 (40.8)3 408 (39.8)3 < .0001 
BMI (kg/m2) 29.2 ± 6.33 28.8 ± 5.12 28.8 ± 5.12 28.4 ± 4.72 27.2 ± 4.01 < .0001 
Hypertension 285 (10.7)1 1000 (14.9)2 1492 (24.7)3 1059 (34.0)4 444 (43.3)5 < .0001 
Diabetes 83 (3.1)1 273 (4.1)1 382 (6.3)2 248 (8.0)3 95 (9.3)3 < .0001 
Current smoker 416 (16.2)4 892 (13.7)3 633 (10.8)2 196 (6.6)1 53 (5.3)1 < .0001 
Obesity 1046 (39.3)4 2410 (36.0)2,3 2259 (37.4)3,4 1072 (34.4)2 255 (24.9)1 < .0001 
Poor CRF 866 (32.5)4 1532 (21.4)1,2 1245 (20.6)1 724 (23.3)2,3 278 (27.1)3 < .0001 
Deaths 40 (1.5)1 158 (2.4)1 287 (4.8)2 437 (14.0)3 350 (34.2)4 < .0001 
   CV death 11 (0.4)1 50 (0.8)1 69 (1.1)1 133 (4.3)2 142 (13.8)3 < .0001 
   Non-CV death 29 (1.1)1 108 (1.6)1 218 (3.6)2 304 (9.8)3 208 (20.3)4 < .0001 
Continuous data are presented mean ± SD; categorical data as N (percentage of sample). 
BMI = body mass index, CRF = cardiorespiratory fitness, CV = cardiovascular 
Poor cardiorespiratory fitness defined as functional aerobic capacity (FAC) < 80% predicted for age and sex 
on exercise test. 
Different superscripts indicate a statistically significant difference between age groups. Superscript = 1 is 




Diabetes and hypertension rates increased progressively with age, while obesity and 
current smoking showed an opposite trend. Not surprisingly, there were relatively more 
women in the older age groups. Poor cardiorespiratory fitness (CRF) – identified by an 
FAC < 80% – was highest in the youngest age group, likely reflecting referral bias in 
younger patients. 
For our diabetes project we initially identified 101544 exercise tests over the study 
period to identify 21,396 patients meeting study criteria. Reasons for exercise testing 
included symptoms in 42% (predominantly chest pain, 31%) and referral to preventive 
cardiology for exercise prescription in the remaining 58%. Of these patients, 1200 had 
diabetes (5.4%), predominately type 2 diabetes; type 1 diabetics represented a small 
portion of the diabetic patients (N = 137, 11.4%). Clinical characteristics of the patients 
are presented according to the presence of diabetes in Table 2.   
 









(N = 1200) 
P-value 
Age, (mean ± SD) (years) 50.4 ± 11.2 54.7 ± 11.0 <.001 
Female (n, %) 7011 (34.7) 394 (32.8) .18 
Body Mass Index, mean (kg/m2) 28.5 ± 5.3 31.7 ± 6.1 <.001 
Obesity (n, %) 6990 (34.6) 702 (58.5) <.001 
Hypertension (n, %) 4156 (20.6) 622 (51.8) <.001 
Smoking history (n, %) 8414 (43.2) 587 (50.8) <.001 
Current Smoking (n, %) 2302 (11.8) 134 (11.6) .83 
Aspirin (n, %) 5190 (25.7) 521 (43.4) <.001 
ACE-inhibitor therapy (n, %) 1180 (5.8) 400 (33.3) <.001 
ARB therapy (n, %) 272 (1.4) 53 (4.4) <.001 
Beta-blockers (n, %) 1719 (8.5) 153 (12.8) <.001 
Calcium channel blockers (n, %) 742 (3.7) 92 (7.7) <.001 
Statins (n, %) 2212 (11.0) 337 (28.1) <.001 
Continuous data are presented mean ± SD, categorical data as percentage of sample. 





Approximately 90% were Caucasian, 3% African American, 7% other race. In 
general, the cardiovascular risk factor burden was low, consistent with the higher socio-
demographic characteristics of the cohort and the exclusion of baseline cardiovascular 
disease. Among the diabetic patients, 352 (29%) were on insulin therapy, 625 (52%) 





















4.2. Exercise Test Results  
Table 3 provides the exercise test data for the full clinical cohort of 19,551 patients.  
Table 3. Exercise test results for the full clinical cohort. 
 
Age: 30-39 
N = 2664 
Age: 40-49 
N = 6703 
Age: 50-59 
N = 6047 
Age: 60-69 
N = 3112 
Age 70-79 
N = 1025 
P 
FAC (%) 88.4 ± 19.31 94.9 ± 20.22 97.1 ± 21.13 96.9 ± 23.53 93.8 ± 24.72 < .0001 
Resting HR (bpm) 78.7 ± 13.25 77.1 ± 12.84 76.4 ± 12.73 75.5 ± 12.92 74.0 ± 12.41 < .0001 
Peak exercise HR (bpm) 176.6 ± 15.35 170.8 ± 15.74 162.9  ±16.03 152.7 ± 17.32 142.7 ± 17.31 < .0001 
Percent pred. peak HR 96.3 ± 8.31 97.6 ± 8.82,3 98.0 ± 9.53 97.1 ± 10.92 95.9 ± 11.51 < .0001 
   HR-lowering drug use 142 (5.3)1 436 (6.5)1 563 (9.3)2 424 (13.6)3 196 (19.2)4 < .0001 
   Peak HR < 85% pred. 241 (9.1)1 568 (8.5)1 583 (9.6)1 415 (13.3)2 169 (16.5)3 < .0001 
HR recovery 21.2 ± 8.15 20.5 ± 8.04 18.9 ± 7.93 16.0 ± 7.52 12.9 ± 7.41 < .0001 
   HR recovery < 13 bpm 340 (12.8)1 993 (14.8)1 1279 (21.2)2 1022 (32.8)3 512 (50.0)4 < .0001 
Resting SBP (mmHg) 118.8 ± 14.91 120.0 ± 15.62 124.0 ± 17.33 129.5 ± 18.74 133.2 ± 20.35 < .0001 
Resting DBP (mmHg) 79.7 ± 11.02 79.7 ± 11.12 80.5 ± 10.83 79.9 ± 10.92,3 77.9 ± 11.31 < .0001 
Peak SBP (mmHg) 171.0 ± 23.61 174.1 ± 23.62 179.4 ± 24.63 182.3 ± 25.24 177.4 ± 20.23 < .0001 
Peak DBP (mmHg) 72.9 ± 16.81 74.9 ± 15.82 77.4 ± 15.53 78.7 ± 15.14 77.2 ± 14.83,4 < .0001 
Highest RPE 18.3 ± 0.84 18.3 ± 0.83,4 18.2 ± 0.83 18.0 ± 0.92 17.9 ± 1.01 < .0001 
Positive exercise ECG 17 (0.6)1 150 (2.2)2 266 (4.4)3 217 (7.0)4 95 (9.3)5 < .0001 
Abnormal exercise ECG 62 (2.3)1 300 (4.5)2 474 (7.8)3 356 (11.4)4 146 (14.2)5 < .0001 
Continuous data are presented mean ± SD; categorical data as number (percentage of sample). 
FAC = functional aerobic capacity, HR = heart rate, SBP = systolic blood pressure, DBP = diastolic 
blood pressure, RPE = rating of perceived exertion, ECG = electrocardiogram 
Functional aerobic capacity defined as 100% x actual time/predicted time on Bruce protocol for age 
and sex. 
Rating of perceived exertion measured on standard Borg Scale (6 – 20). 
Positive exercise electrocardiogram defined by standard methods. 
Abnormal exercise electrocardiogram defined as positive or abnormal but not diagnostic due to resting 
ST-T abnormalities. 
Different superscripts indicate a statistically significant difference between age groups.  






     Because of the large sample size, even minor differences, such as in resting HR or 
highest rating of perceived exertion reached statistical significance, though some age 
trends were pronounced, such as the well-documented trend towards decreasing peak 
exercise HR with age (33). HR recovery also declined significantly with age, while the 
proportion of patients with HR recovery < 13 bpm increased significantly. Not 
surprisingly, the portion of patients taking HR-lowering drugs increased significantly 
with age. The frequency of both positive and all abnormal exercise ECGs also increased 
steadily with age. 
4.3. Factors Affecting Heart Rate Recovery 
For the next step in the analysis, stepwise multivariate regression to determine 
factors significantly affecting HR recovery was performed (Table 4.)   















Intercept 31.79 0.29   12107.3 <.0001 
Age -0.21 0.0055 0.071 0.071 1445.6 <.0001 
Poor CRF -3.92 0.14 0.063 0.134 1368.1 <.0001 
Obesity -1.32 0.12 0.0060 0.140 132.5 <.0001 
Current smoking -1.90 0.18 0.0051 0.145 113.2 <.0001 
Hypertension -1.08 0.15 0.0027 0.148 60.9 <.0001 
Diabetes -1.46 0.25 0.0016 0.149 35.8 <.0001 
CRF = cardiorespiratory fitness 
The N for Table 4 was 18887, as 664 patients (3.4%) had one missing covariate, 
principally smoking status. Intercept and age were highly significant in the regression, 
and 5 other factors – poor CRF, obesity, current smoking, hypertension, and diabetes – 
all showed significant (negative) effects on HR recovery, whereas sex, taking a HR-
lowering drug, and an abnormal exercise ECG did not affect HR recovery significantly. 
Only age and poor CRF contributed more than 1% to the model R2. Based on these 
results, we formed our pure cohort by eliminating patients with the 6 HR recovery-





4.4. Heart Rate Recovery in Age Groups 
Table 5 shows means, medians, and interquartile range for HR recovery, and 
percent of patients with HR recovery less than the traditional cut-point of 13 bpm in the 
first minute of active recovery according to decade of age in the pure cohort.   
 
Table 5. Heart rate recovery distribution in the pure cohort. 
 
Age: 30-39 
N = 1056 
Age: 40-49 
N = 2967 
Age: 50-59 
N = 2390 
Age: 60-69 
N = 1116 
Age 70-79 
N = 323 
P 
Resting HR  
(bpm) 
76.1 ± 12.72 74.8 ± 12.41 74.6 ± 12.11 75.1 ±12.11,2 73.8 ±11.11 <.001 
Peak exercise HR 
(bpm) 
182.4 ± 11.45 176.4 ± 11.94 168.6 ± 12.93 159.1 ± 13.72 149.4 ± 14.61 <.001 
Female  
(%) 
327 (31.0)1 990 (33.4)1,2 880 (36.8)2 509 (45.6)3 147 (45.5)3 <.001 
HR-lowering drug use 
(%) 
23 (2.2)1,2 54 (1.8)1 60 (2.5)1,2 43 (3.8)2 23 (7.1)3 <.001 
Mean HR recovery 
(bpm) 
22.9 ± 8.34 22.3 ± 8.24 21.1 ± 8.03 18.4 ± 7.42 14.9 ± 7.31 <.001 
Median HR recovery 
(bpm) 
22 22 21 18 14  
Interquartile range 
(bpm) 
17 - 28 17 - 27 16 - 26 13 - 23 10 - 20  
HR recovery < 13 bpm 
(%) 
87 (8.4)1 298 (10.0)1 311 (13.0)2 240 (21.5)3 134 (41.5)4 <.001 
Continuous data are presented mean ± SD; categorical data as number (percentage of sample). 
HR = heart rate 
Pure cohort created by excluding patients with hypertension, diabetes, current smoking, obesity (BMI ≥ 30 
kg/m2), and poor cardiorespiratory fitness (functional aerobic capacity < 80% age-sex predicted). 
Different superscripts indicate a statistically significant difference between groups.  




We propose that these data represent the true effect of age on HR recovery. At each 
age group, HR recovery in the pure cohort was higher than in the full cohort, as 
expected.  Average HR recovery is relatively constant through ages 30 – 39, while 
through ages 50 – 59 it begins to decrease more rapidly as age increases. The portion of 
patients with a HR recovery below the traditional cut point of 13 bpm is only 8.4% at 
age 30 – 39 but has risen to 41.5% by age 70 – 79.   
4.5. Outcomes by Abnormal Heart Rate Recovery 
There were a total of 1,271 deaths (6.5%) in the full cohort over an average follow-
up of 12.4 ± 5.0 years. Consistent with exclusion of baseline CV disease and residence 
in a state (Minnesota) with overall low CV death rates, there were actually more non-
CV deaths (867, 4.4%) than CV deaths (405, 2.1%). Not surprisingly, women were at a 
lower age-adjusted risk of death (0.70 with 95% confidence interval [0.62 – 0.90]), 
compared to men. 
Using the full clinical cohort, an abnormal HR recovery by the traditional value of < 
13 bpm in the first minute post-peak exercise during active recovery was a significant 
risk factor for death from any cause, CV death, and even non-CV death in this primary 
prevention cohort. Hazard ratios for an abnormal HR recovery predicting death, CV 






Figure 5. Hazard ratios with 95% confidence intervals for an abnormal heart rate (HR) recovery 
predicting death, cardiovascular (CV) death, and non-CV death.  
Three models are shown for each outcome: unadjusted; adjusted for age and sex; fully adjusted for age, 
sex, diabetes, hypertension, obesity, current smoking, and poor cardiorespiratory fitness.   
Hazard ratios for CV and non-CV death are compared by the Z-score method. 
 
Three models are shown for each outcome: unadjusted; adjusted for age and sex; 
and fully adjusted for age, sex, diabetes, hypertension, obesity, current smoking, and 
poor CRF. The hazard ratios in all models for all outcomes are statistically significant. 
The hazard ratio for abnormal HR recovery for CV versus non-CV death was 
significantly higher in the unadjusted (P<.0001), age-sex adjusted models (P<.001), and 
fully adjusted (P<.02) models. We have therefore demonstrated that an abnormal HR 
recovery is a significant predictor of death, CV death, and even non-CV death in our 
primary prevention cohort. 
For further analyses, we focused on CV mortality since its association with 
abnormal HR recovery was strongest. We divided the full cohort according to 3 age 
groups, 30 – 59 (based on the minimal change in HR recovery across this age range as 
mentioned above), then 60 – 69, and 70 – 79, as HR recovery declined significantly 
over these older age groups. Hazard ratios for CV death according to HR recovery in the 
3 age groups are shown in Figure 6.  Hazard ratios were statistically significant in all 





Figure 6. Hazard ratios with 95% confidence intervals for an abnormal heart rate (HR) recovery 
predicting cardiovascular (CV) death stratified by age, sex, presence of obesity, hypertension, diabetes, 
current smoking, use of HR-lowering drug, and level of cardiorespiratory fitness (CRF). 
Poor CRF refers to functional aerobic capacity (FAC) < 80%, reduced CRF to FAC 80 – 99%, and 
normal CRF to FAC ≥ 100% predicted. All models are fully adjusted for age, sex, diabetes, hypertension, 
obesity, current smoking, and poor CRF. Hazard ratios for CV death are compared by the Z-score 
method.  
Hazard ratio bars filled with striped pattern indicate non-significant findings.   
 
Figure 6 also shows the predictive value of abnormal HR recovery according to sex, 
3 levels of CRF, smoking status, diabetes, hypertension, obesity, and use of a HR-
lowering drug. Abnormal HR recovery significantly predicted outcomes in all sub-
groups except current smokers, patients with normal CRF (≥ 100% FAC), and patients 
taking a HR-lowering drug; in these sub-groups, the confidence intervals in the Hazard 
Ratios included 1.0. As noted in the displayed P-values, there was a significant 
difference in the hazard ratios in poor versus normal CRF, while the differences in 
hazard ratios according to HR-lowering drug and current smoking were of borderline 
significance. On the other hand, abnormal HR recovery did not perform differently in 
males versus females, in reduced versus normal CRF, among the three age groups, or in 




4.6. Exercise Test Results by Diabetes 
Exercise test results by diabetics are given in Table 6.   









(N = 1200) 
P-value 
Exercise time (min) 9.2 ± 2.5 7.5 ± 2.2 <.001 
FAC (%) 96 ± 22 82 ± 22 <.001 
Resting HR (beats/minute) 77 ± 13 81 ± 14 <.001 
Peak HR (beats/minute) 165 ± 19 154 ± 20 <.001 
HR reserve (beats/minute) 88 ± 19 73 ± 19 <.001 
HR recovery (beats/minute)a 19 ± 9 15 ± 8 <.001 
HR recovery < 13 beats/minute (%)  4243 (21.0) 463 (38.6) <.001 
Chronotropic Indexb 0.99 ± 0.20 0.86 ± 0.22 <.001 
Chronotropic Index < 0.8 (%) 3329 (16.5) 478 (39.8) <.001 
Resting systolic BP (mmHg) 123 ± 18 128 ± 19 <.001 
Resting diastolic BP (mmHg) 80 ± 11 78 ± 11 <.001 
Peak systolic BP (mmHg) 177 ± 26 184 ± 27 <.001 
Peak diastolic BP (mmHg) 77 ± 16 78 ± 16 <.001 
Peak RPE 18.1 ± 1.0  18.0 ± 1.0 .06 
Positive ECG (%) 923 (4.6) 103 (8.6) <.001 
Abnormal ECG (%)c 1593 (7.9) 141 (11.8) <.001 
Continuous data are presented mean ± SD, categorical data as percentage of sample. 
Abbreviations: BP = Blood Pressure; CI = Chronotropic Index, ECG = electrocardiogram;  
FAC = Functional Aerobic Capacity; HR = Heart Rate; RPE = Rating of Perceived Exertion  
a  Heart rate recovery was defined as peak HR minus HR at 1 minute of active recovery (1.7 MPH/0% 
grade) 
b CI was defined as the ratio of observed HR reserve to predicted HR reserve for a large cohort of healthy 
subjects previously defined in our laboratory 
c Abnormal exercise ECG was defined as any test with ≥ 1.0 mm ST deviation irrespective of whether the 





FAC based on age-sex adjusted performance time was greater for non-diabetics 
versus diabetics; it was near 100% for the non-diabetic group (32). Reason for 
termination was symptom-limited in 96% of tests; 2% of tests were terminated at patient 
request and another 2% according to judgment of the test monitor. The rating of 
perceived exertion at peak exercise averaged ~ 18 on the 6-20 Borg Scale in both 
groups (34).    
Diabetics had higher resting HR and lower peak HR, HR reserve, CI and HR 
recovery compared to non-diabetics. Diabetic patients also had higher resting and peak 
exercise systolic blood pressure. Both positive exercise ECG and abnormal exercise 
ECG were more common in patients with diabetes. The prevalence of both abnormal 
HR recovery (≤ 13 beats/minute) and abnormal CI (< 0.8) was significantly higher in 
diabetics versus non-diabetics. A low CI using the established cut-point of < 0.8 is 
present in only 16% of the non-diabetics versus 39% of the diabetic patients. Using the 
traditional cut-point of < 13 beats/minute, abnormal HR recovery is present in only 22% 
of non-diabetics versus 39% of diabetics. The prevalence and significance of CI is likely 
altered by differential use of HR-lowering drugs in diabetics versus non-diabetics, but 
HR recovery, being affected principally by parasympathetic tone, should not be subject 
to effect of these drugs. Among the non-diabetic patients, 14,048 (70%) had no exercise 
HR abnormality (abnormal HR recovery or low CI), 4,724 (23%) had one abnormality 
and 1,424 (7%) had two abnormalities, while among diabetic patients, 539 (45%) had 















4.7. Effect of Diabetes on Heart Rate Variables 
Table 7. shows the effect of diabetes on exercise HR variables controlling for 
differences between diabetics and non-diabetics in variables potentially affecting 
exercise HR by use of multivariate linear regression.  










Resting HR (bpm) + 4.9 <.001 + 2.9 <.001 
Peak HR (bpm) - 6.4 <.001 - 4.5 <.001 
HR reserve (bpm) - 11.4 <.001 - 7.4 <.001 
HR recovery (bpm) - 3.0 <.001 - 1.9 <.001 
Chronotropic Index (CI) - 0.128 <.001 - 0.08 <.001 
Abbreviations: HR = Heart Rate 
 
In the simple model age, sex and HR-lowering drugs were added to diabetes, while in 
the full model we extended it with current smoking, hypertension, abnormal exercise 
ECG, oral hypoglycemic drugs and insulin. Diabetes showed significant HR modifying 
effects in both models. In the simple model, all factors showed significant effects on 
each HR variable, except for female sex on HR recovery. In the full model age, female 
sex, HR-lowering drug, smoking, hypertension and insulin had significant HR - 
lowering effects on all HR variables, while oral hypoglycemic drugs did not have a 
significant effect on resting HR, peak HR and on HR recovery; and abnormal exercise 










4.8. Mortality by Diabetes and Impaired Exercise HR 
Overall mortality was low. There were 1362 deaths (6.4%) over a mean follow-up 
of 11.9 ± 4.9 years. Differences in survival in diabetics and non-diabetics according to 
these two exercise HR variables are shown in Figure 7.   
Figure 7. Survival for the first 15 years of follow-up according to presence or absence of diabetes and 
normal or low chronotropic index (CI) [A] and normal or abnormal heart rate (HR) recovery [B].   
The reduction in survival for abnormal CI (Figure 7A) is very similar to the 
reduction seen with abnormal HR recovery (Figure 7B) for both diabetic and non-
diabetic patients. In multivariate analysis using the simple model, which included age, 
sex, and use of HR-lowering drug, both CI < 0.8 and abnormal HR recovery contributed 
independently to the risk of death significantly and similarly in both diabetic and non-
diabetic patients. The hazard ratio for CI < 0.8 was 2.21 with 95% confidence interval: 
1.62 – 3.00, P<.001 in diabetics and 1.94 with 95% confidence interval: 1.71 – 2.20, 
P<.001 in non-diabetics. Abnormal HR recovery similarly predicted mortality (hazard 
ratio 2.21 with 95% confidence interval: 1.60 – 5.05, P<.001 in diabetics versus 1.75 
with 95% confidence interval: 1.55 - 1.97, P<.001 in non-diabetics). Only minor 




In Figure 8 we further explore the relationship of mortality with the two most 
commonly utilized variables of exercise HR – abnormal CI and abnormal HR recovery– 









Figure 8. Hazard ratios with 95% confidence intervals for mortality by diabetes and number of exercise 
heart rate (HR) abnormalities (chronotropic index (CI) and HR recovery). Patients with no diabetes and 0 
exercise HR abnormalities form the referent group. 
Mortality increases with the number of exercise HR abnormalities in both diabetic 
and non-diabetic patients. To highlight the importance of exercise HR as a predictor of 
mortality, we compared diabetics with normal exercise HR to non-diabetics with one or 
two exercise HR abnormalities. Using non-diabetics with no HR abnormalities as the 
referent, the mortality of diabetics with no HR abnormalities (Hazard Ratio = 1.56 [95% 
confidence interval: 1.14 - 2.12]) is essentially the same as non-diabetic patients with 
one HR abnormality (Hazard Ratio = 1.50 [95% confidence interval: 1.31 - 1.71]), and 
the 95% confidence intervals are fully overlapped. Looking further at the importance of 
exercise HR in prognosis, the mortality of non-diabetic patients with both HR 
abnormalities is significantly higher (Hazard Ratio = 2.78 [95% confidence interval: 
2.38 – 3.24]) compared to diabetics with no HR abnormalities with no overlap in the 







We give a detailed description of the role and prognostic performance of prognostic 
parameteres including HR recovery in a general population. Moreover, we show that 
HR recovery is associated with a number of CV risk factors including diabetes, 
hypertension, current smoking and poor CRF but is not affected by sex or use of HR 
lowering drug. Exercise test is an important prognostic tool to predict mortality. Using 
non-ECG parameters such as HR recovery we can predict not only total mortality but 
also abnormal HR recovery, which is an even stronger predictor of CV death and 
predicts non-CV death as well. While HR recovery performs equally well in all age 
groups and in both men and women, it is less useful in patients with normal CRF or in 
those taking a beta-blocker.  
If we study exercise HR responses in patients with diabetes, we can see that heart 
rate responses to exercise are more frequently impaired versus non-diabetic patients. 





















5.1. Prognostic Performance of Heart Rate Recovery 
This retrospective study confirmed the hypothesis that HR recovery has prognostic 
significance in a primary prevention cohort of almost 20,000 patients without 
documented history of known CV disease. We show that HR recovery is a significant 
predictor not only of total and CV death but of non-CV death as well. HR recovery is 
impaired by a number of CV risk factors including diabetes, hypertension, obesity, 
smoking, and poor CRF. HR recovery decreases significantly with age, especially above 
50 years, but it performs equally well in all adult age groups. We also show that HR 
recovery predicts CV death equally in men versus women and patients with and without 
hypertension, diabetes, or obesity, but its prognostic performance is limited in patients 
with normal CRF, current smokers, and those taking HR-lowering drugs. 
5.1.1. Predictive Value of Heart Rate Recovery 
The first comprehensive study of HR recovery was from Lauer et al. in 1999, which 
included patients who were referred for a first symptom-limited exercise test and single-
photon-emission computed tomography with thallium scintigraphy. These patients were 
candidates for initial angiography (2). Lauer postulated that HR recovery is a reflection 
of decreased vagal activity and established the formula calculating HR recovery as peak 
HR – HR at 1 minute in the active recovery and defined it as abnormal if < 13 bpm.   
Extended analyses on 9,454 patients undergoing myocardial perfusion imaging 
confirmed that HR recovery is a powerful predictor of overall mortality independent of 
workload, presence of myocardial perfusion defects, and DTS (3). Other studies have 
investigated the predictive value of HR recovery in various high risk populations such 
as heart failure, diabetes, and coronary artery disease (5,35-38). They all confirmed that 
HR recovery is an independent predictor of both CV and total mortality in their specific 
patient populations. In an American Heart Association statement published in 2005 in 
Circulation, exercise testing was identified as an important tool of assessing and 
refining prognosis, particularly when emphasis is placed on non-ECG measures 
including HR recovery (39).   
Data on HR recovery in lower risk cohorts is more limited. The prognostic 
importance (all-cause mortality and non-fatal myocardial infarction) of HR recovery has 




identified the prognostic role of HR recovery in 2014 in a smaller population with 6,546 
patients focusing on the association of HR recovery with exercise test parameters and 
all-cause mortality (41). The ability of HR recovery to predicted non-CV mortality has 
not been previously addressed. 
5.1.2. Factors Affecting Heart Rate Recovery 
Two prior studies investigated the effect of sex on HR recovery and mortality 
(42,43).  Both suggested that abnormal HR recovery was independent of sex and had 
similar prognostic value in both men and women, as our study has confirmed. Two prior 
studies reported HR recovery in older patients (44,45), but they did not compare the 
impact of age on its prognostic value, as we have done here. 
Though obesity, hypertension and diabetes are all affected the HR recovery, 
abnormal HR recovery had similar prognostic significance in patients with or without 
obesity, hypertension and diabetes. Smokers also had lower HR recovery but abnormal 
HR recovery was not a significant predictor of CV death in current smokers. We 
speculate that the profound effect of smoking on CV mortality may follow a different 
mechanism (acute plaque rupture) than other risk factors including age, sex, obesity, 
hypertension, and poor CRF, but the limited utility of HR recovery in current smokers 
may also reflect low statistical power due to the relatively small number of current 
smokers in the cohort (11%). 
Another important clinical question about HR recovery interpretation is the use on 
HR-lowering drug, mainly beta-blockers. Of the 1761 (8.9%) patients taking any HR-
lowering drug, almost all (1667, 94.7%) were taking a beta-blocker. Although there was 
no difference in HR recovery in patients taking or not taking HR-lowering drug, an 
abnormal HR recovery did not significantly predict CV death in patients taking a HR-
lowering drug. We explain this paradoxical finding by pointing out that an abnormal 
HR recovery indicates reduced parasympathetic tone with a resultant imbalance 
between sympathetic and parasympathetic tone. Blocking sympathetic tone may restore 
that balance and eliminate the hazard associated with the abnormal HR recovery. 
However, as may also have been the case with current smoking, the small number of 
patients in this primary prevention cohort taking beta blocker may have also limited our 
ability to show significance in this group. Prior studies have tested the role of beta-




HR recovery, but they included patients with CV diseases (46). Karnik et al. stated that 
beta-blocker use improved HR recovery in patients with positive exercise stress 
echocardiography, and that it does not affect HR recovery in patients with negative 
exercise stress echocardiography, and can be used for mortality prediction (47) – the 
latter finding is in contrast with what we have observed in a low risk primary prevention 
cohort. Also in apparent contrast to our findings, the study of Myers et al., which 
included 1,910 male veterans, suggested that beta-blockade had minimal impact on the 
prognostic power of HR recovery (48). The interaction of beta blockers and HR 
recovery may require further clarification. 
Our study is also the first to stratify HR recovery according to CRF. Better CRF is 
clearly associated with better HR recovery, while the prognostic significance of an 
abnormal HR recovery is inversely related to CRF. The limited utility of HR recovery in 
patients with normal CRF may be a consequence of the low rate of CV mortality (109 
deaths, 1.4%) in this sub-group. The principle that “fitness trumps other risk factors” 
has also been observed with respect to obesity and diabetes (49,50) – and also applies to 
ST segment changes during exercise (1,51). What is more important, perhaps, is the 
observation that abnormal HR recovery is a strong predictor of CV death in patients 
with poor CRF, indicating that abnormal HR recovery is more than just 
“deconditioning”. 
5.1.3. Strength and Limitations 
The strengths of our study include a large consecutive cohort with complete 
mortality follow-up over a long time period. We have also divided mortality according 
to CV and non-CV death. Exercise test data were robust and complete, and important 
data on comorbidities and pharmacotherapies were available. Our study reflected the 
limited racial diversity seen in Minnesota, so our results may not be applicable to more 
diverse racial or ethnic groups. Overall mortality was low, reflecting the status of 
Minnesota as a state with low total and CV mortality. However, we might speculate that 
exercise HR responses might be even more important in a higher risk population. 
 Exercise tests were conducted in a clinical environment, and patients were 
instructed to exercise to subjective fatigue. Gas exchange was not measured to confirm 




time point. The exercise test may thus reflect recent, rather than lifetime physical 
activity patterns, for some patients. 
We identified HR recovery as the change during the first minute of the active 
recovery period; we thus cannot comment on the value of HR recovery as measured 
over different time points, such as at 2, 3 or 5 minutes post exercise or where an active 
recovery was not employed (as in stress echocardiography).  
For our non-imaging non-cardiopulmonary stress tests, we generally used the Bruce 
protocol, so we did not have sufficient number of patients of cycle ergometer or 
treadmill tests on other protocols to perform similar analyses of HR recovery.   
 
5.2. Impaired Exercise Heart Rate Response in Diabetes 
The principal findings of this study are: 1) exercise HR responses are more 
frequently impaired in diabetic patients versus non-diabetic patients; and 2) abnormal 
HR response is predictive of excess long-term mortality in both diabetic and non-
diabetic patients. Resting HR was higher, while peak HR, HR reserve, HR recovery, 
and the CI were significantly lower in diabetic versus non-diabetic patients after 
adjustment for age, sex, and use of HR-lowering drugs. An extended adjustment for 
current smoking, diabetes, abnormal exercise ECG, FAC, BMI, and type of diabetic 
treatment did not alter the results appreciably. Both CI and abnormal HR recovery were 
predictors of total long-term mortality in diabetics – as they were also in non-diabetics -
- after both the simple and extended multivariate adjustments. To demonstrate the 
importance of exercise HR abnormalities in determining mortality in diabetic patients, 
we showed that diabetics with normal CI and HR recovery had similar mortality to non-
diabetics with one of the two exercise HR abnormalities – and less than one-third the 
mortality of non-diabetics with both exercise HR abnormalities. 
5.2.1. Clinical Importance 
There are no comparable studies examining exercise HR responses in a cohort with 
a large number of diabetic patients with outcome data, though several studies have 
reported HR response to exercise testing in diabetic patients. The Look AHEAD study 
did report exercise test results, including abnormal HR recovery, on 5,783 




tests were performed at baseline, so there were no outcomes (9). They used a special 
protocol, not the Bruce as in our study. HR recovery was obtained 2 min after exercise 
in supine position, and it was considered abnormal if < 23 beats/minute. HR recovery 
according to their definition was abnormal in only 5% of the patients, versus 39% in our 
study according to the commonly accepted Lauer definition (21). Because of the 
different protocol and different determination of HR recovery, we cannot adequately 
compare their results to ours.  
One small study suggested that abnormal HR recovery predicts severity of ischemia 
in diabetics patients using myocardial perfusion imaging (7), and one small study using 
stress echocardiography found impaired exercise HR responses similar to our study 
(52). However, HR recovery did not identify a significant, independent survival benefit 
of revascularization above and beyond ischemic burden and exercise capacity over 8 
years of follow-up (53). 
Data from the prospective CARDIA study suggest that abnormal HR recovery 
predicts the future development of type 2 diabetes (54). This is an important observation 
lending support to the proposition that abnormal HR responses are a physiologic 
consequence of diabetes, and that the abnormal exercise HR variables found in our 
study are not simply due to the fact that diabetics exercised at a lower level of effort 
than the non-diabetics. 
Cardiac autonomic neuropathy is an important and common consequence of 
diabetes mellitus and may directly play a key role in excess late mortality, as well as 
being a marker of cardiovascular dysfunction. It may induce arrhythmias, myocardial 
ischemia or sudden cardiac death (55). Sympathetic tone determines peak exercise HR 
while parasympathetic tone affects both resting HR and recovery of HR immediately 
after exercise.  
We found marked changes in resting HR, peak HR, HR recovery, and the CI in 
diabetic patients suggesting impairment of autonomic function. Elevated resting HR 
may reflect an imbalance in autonomic function favoring sympathetic over 
parasympathetic activity, likely due to decreased parasympathetic tone. Increased 
sympathetic activity has been associated with reduced insulin sensitivity, higher blood 
pressure, obesity, which leads to metabolic syndrome,(56) so this shift in sympathetic-




resting HR was identified as a marker for identifying the risk of undiagnosed type 2 
diabetes mellitus (57-59). It is a predictor of cardiac autonomic neuropathy in type 1 
diabetes mellitus (60). In our study we found lower peak HR in diabetic patients 
compared to patients without diabetes, suggesting a reduction in the ability to enhance 
sympathetic tone. As a consequence of higher resting HR and lower peak HR, the 
calculated CI was lower in diabetic patients, which means a reduced ability to increase 
appropriately HR with exercise – and to perform to a good level on the test. These 
variables all reflect the altered sympathetic-parasympathetic balance (61). 
Diabetic patients had lower HR recovery compared to the non-diabetics, which 
further reflects their parasympathetic impairment. Blunted post-exercise 
parasympathetic reactivation may be the primary cause of lower HR recovery (62). In 
earlier data, HR recovery was shown as an accurate diagnostic test for cardiac 
autonomic neuropathy in type 2 diabetes (63). Both chronotropic incompetence and 
abnormal HR recovery have been shown to associate independently with increased 
mortality and sudden cardiac death in patients with and without cardiovascular diseases 
(2,21,29,41,48,64). In our study abnormal HR recovery was as common as chronotropic 
incompetence in diabetic patients (40% versus 39%, respectively), suggesting that 
diabetics equally have both sympathetic and parasympathetic impairment, and the effect 
on mortality of abnormal HR recovery was identical compared to the effect of low CI in 
diabetic patients (hazard ratio 2.21 for both variables). Diabetic patients with both 
exercise HR abnormalities suffered a combined impact of hazard ratio of 3.00 with 95% 
confidence interval: 2.25 - 4.10. 
The most commonly used method to assess cardiac autonomic neuropathy is the 
measurement of beat to beat variability of the cardiac RR intervals called HR 
variability, which reflects the balance of autonomic function (65). This is mainly a 
resting variable and it has been shown to decrease in many other cardiovascular and 
non-cardiac diseases.  Using exercise stress testing, we can get more information about 
not only resting but also exercise HR variables, which may be more specific for diabetes 
and can predict the mortality as well.    
The exercise HR variables have potential clinical utility, not only with risk 
stratification, but may also direct us toward potentially survival improving interventions 




are likely inextricably intertwined. Diabetics had significantly higher BMI and lower 
FAC compared to non-diabetics. Moreover, the presence of both abnormal CI and 
abnormal HR recovery were strongly related to fitness level as determined by FAC. For 
FAC ≥ 100% versus 80-99% versus < 80%, the presence of abnormal CI increased from 
5.1% to 14.3% to 42%, respectively (P < .001). A similar if not quite so dramatic trend 
was seen for abnormal HR recovery: 14.0%, 19.3%, and 38.1%, respectively (P < .001). 
Though we do not have sufficient data on physical activity amount and intensity to 
directly substantiate that these differences are due to physical activity levels, there is a 
strong implication that being more active and getting more fit will improve the HR 
response and reduce risk. 
There was a similar trend for abnormal CI and abnormal HR recovery versus BMI.  
For BMI < 25 kg/m2 versus 25-29.9 versus 30-34.9 versus ≥ 35, the presence of 
abnormal CI was 11.6%, 13.6%, 21.4%, and 35.2%, respectively (P < .001). For 
abnormal HR recovery, the trend showed 18.4%, 20.0%, 23.2%, and 32.7% presence 
with increasing BMI (P < .001). 
The observation that insulin more than oral hypoglycemic agents adversely affect 
exercise HR variables may reflect the fact that insulin use may be a surrogate marker for 













5.2.2. Strength and Limitations 
The strengths of our study include a large consecutive cohort with complete 
mortality follow-up over a long time period. Exercise test data were robust and 
complete, and important data on comorbidities and pharmacotherapies were available.  
Our study reflected the limited racial diversity seen in Minnesota and our results may 
not be applicable to more diverse racial or ethnic groups. Overall mortality was low, 
even in the diabetic patients, reflecting the status of Minnesota as a state with low total 
and cardiovascular mortality. We might speculate that exercise HR responses might be 
even more important in a higher risk population. 
We did not separate diabetic patients into type 1 and type 2, though our experience 
is that the overwhelming majority of diabetic patients referred for stress testing are type 
2. Duration of diabetes was not recorded in the database, nor was the degree of control 
according to hemoglobin A1c. 
The stress tests were conducted in clinical circumstances, and patients were 
instructed to exercise to subjective fatigue. Gas exchange was not measured to confirm 
the level of metabolic effort by respiratory exchange ratio. The ratings of perceived 
exertion, however, were essentially identical between the diabetic and non-diabetic 
patients, suggesting that exercise HR was not just a consequence of effort. In addition, 
the observed differences in resting HR – and its contribution to CI – could not be 












This study confirmed the hypothesis that HR recovery has prognostic significance in 
a primary prevention cohort. A unique finding is that an abnormal HR recovery predicts 
not only total mortality, as previously demonstrated, but it is an even stronger predictor 
of CV death and surprisingly predicts also non-CV death. We demonstrate that impaired 
HR recovery is associated with a number of well-established CV risk factors including 
diabetes, hypertension, current smoking and poor CRF, but it is not affected by the 
patient’s sex or taking a HR-lowering drug. We further show that HR recovery performs 
equally well in all adult age groups and in both men and women and patients stratified 
by obesity, hypertension, or diabetes. On the other hand, HR recovery is less useful in 
patients with normal CRF, in current smokers, or in those taking a beta-blocker. We 
strongly endorse previous recommendations that HR recovery should be measured and 
reported on every exercise test (31). Impaired HR response to exercise are frequently 
seen in patients with diabetes, and this is predictive of excess long-term mortality 
beyond that seen in diabetics with a normal HR response. The stress test in diabetic 
patients yields much more information than just the presence of ischemia by ECG and 
should be interpreted more broadly to include both FAC and exercise HR for risk 
















Exercise test is a widely used diagnostic method, however its prognostic value is not 
enough emphasised in the clinical cardiology practice. This means not only looking at 
the ST segment response, but also accurately reporting and identifying the significance 
of functional aerobic capacity (FAC) and exercise heart rate (HR) responses, including 
the HR recovery.  
Our aim was to give a detailed description of the role and prognostic performance of 
prognostic parameteres on an exercise test including HR recovery in a general 
population and to study the exercise HR responses in a special population of patients 
with diabetes. This study confirmed the hypothesis that HR recovery has prognostic 
significance in a primary prevention cohort. A unique finding is that an abnormal HR 
recovery predicts not only total mortality, as previously demonstrated, but is an even 
stronger predictor of cardiovascular (CV) death and surprisingly predicts also non-CV 
death. We demonstrate that impaired HR recovery is associated with a number of well-
established CV risk factors including diabetes, hypertension, current smoking and poor 
cardiorespiratory fitness (CRF), but is not affected by the patient’s sex or taking a HR-
lowering drug. We further show that HR recovery performs equally well in all adult age 
groups and in both men and women and patients stratified by obesity, hypertension, or 
diabetes. On the other hand, HR recovery is less useful in patients with normal CRF, in 
current smokers, or in those taking a beta-blocker. We strongly endorse previous 
recommendations that HR recovery should be measured and reported on every exercise 
test. Impaired HR response to exercise are frequently seen in patients with diabetes 
versus non-diabetic patients, and this is predictive of excess long-term mortality beyond 
that seen in diabetics with a normal HR response.  
The stress test - both in general population and in diabetic patients - yields much more 
information than just the presence of ischemia by ECG and should be interpreted more 
broadly to include both FAC and exercise HR for risk stratification and, potentially, to 








A terheléses EKG egy széles körben használt diagnosztikus módszer, ennek ellenére a 
prognosztikai értéke nincs megfelelően kihangsúlyozva a kardiológiai gyakorlatban. Az 
ST szakaszok tanulmányozása mellett kiemelt jelentőségű a funkcionális aerob 
kapacitás, valamint a terheléses szívfrekvencia válaszok vizsgálata. 
Az értekezés célja a terheléses EKG vizsgálat során meghatározható prognosztikai 
paraméterek szerepének és prognosztikus értékének vizsgálata normál populációban, 
valamint diabeteses betegek csoportján. Vizsgálataink igazolták hipotézisünket, 
miszerint a szívfrekvencia megnyugvás jelentős prognosztikai jelentőséggel bír a primer 
prevenciós csoportban. Új eredménynek tekintjük, hogy a kóros szívfrekvencia 
megnyugvás nemcsak az összhalálozás prediktora - ahogyan ezt már korábban is 
vizsgálták – hanem erős prediktora mind a kardiovaszkuláris mind a nem 
kardiovaszkuláris halálozásnak. A kóros szívfrekvencia megnyugvás összefügg számos 
kardiovaszkuláris rizikófaktorral, mint például a cukorbetegség, magasvérnyomás, aktív 
dohányzás és a mozgásszegény életmód; azonban nem függ a beteg nemétől és az 
esetlegesen szívfrekvencia csökkentő gyógyszer szedésétől sem. Továbbá bemutattuk, 
hogy a szívfrekvencia megnyugvás hasonlóan megbízhatóan használható a prognózis 
előrejelzésére minden korcsoportban, férfiaknál és nőknél; elhízott, magas vérnyomásos 
és cukorbetegek csoportjaiban is. Mindemelett a szívfrekvencia megnyugvás 
prognosztikus szerepe kevésbé jól értékelhető normál terhelhetőségű betegek körében, 
aktív dohányosoknál és a béta-blokkolót szedők körében. Mindezek alapján a korábbi 
ajánlásoknak megfelelően rendkívül fontos a szívfrekvencia megnyugvás 
meghatározása és értékelése minden egyes terheléses EKG vizsgálat során. Diabeteses 
betegeknél gyakrabban megfigyelhetők a kóros szívfrekvencia válaszok a nem 
diabeteses betegekhez képest, a kóros frekvencia válasszal rendelkező diabeteses 
betegek mortalitása jóval meghaladja a normál szívfrekvencia válasszal rendelkezőkét.  
A terheléses EKG – mind a normál populációban, mind a cukorbetegek körében – 
jelentős többlet információt nyújthat a terhelés által indukált ischaemia jelzése mellett, 
ezért a rizikó meghatározásához szükség van az általunk ismertetett prognosztikus 
paraméterek - beleértve a funkcionális aerob kapacitás és a terheléses szívfrekvencia 
válaszok meghatározására is. Mindezek iránymutatók lehetnek a további terápiában és 
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